LimmaTech Biologics AG, Schlieren, Switzerland
lmtbio.com

LBT-SA7

MULTI-VALENT TOXOID VACCINE

Direct-Acting Large Molecule Therapeutic; Vaccine
LBT-SA7 consists of five components representing toxoids for seven Staphylococcus Aureus (SA) toxins. Due to cross-reactivity, these toxoids elicit protective responses to 12-15 SA toxins. Efficacy of the vaccine components have been shown in various mouse and rabbit models of infection. This is the first entirely non-surface antigen-based vaccine for SA disease. The studies to be performed under CARB-X support will complete the pre-clinical development of the vaccine and transitions the program to phase I clinical trial.

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $168k with potential option payments up to $12.8m. In August 2019, CARB-X awarded an additional $1.62m to IBT to develop a freeze-dried version of the vaccine for use in developing nations where cold-storage systems are not available.

Initial CARB-X Investment Date: October 1, 2017

Read their Spotlight on Science